Medtronic, Arteriocyte ink agreement for cardiac surgery market
Arteriocyte Medical Systems has struck a strategic partnership with Medtronic that includes the acquisition of the Magellan Platelet Business, an international distribution agreement in the cardiac surgery market for the next five years, and a manufacturing services agreement for the Magellan products.

The Cleveland-based Arteriocyte said the Magellan system is currently installed in more than 400 surgical centers throughout North America and Europe.

The medical device company also said that the Magellan System, a biologic concentrator and delivery system, collects and concentrates platelets and white blood cells from a small volume of a patient’s own blood, providing a supply of plasma that serves as a foundation for autologous platelet gel. The Magellan System can accelerate wound healing as well as reduce infection in cardiac surgery, plastic and reconstructive surgery, orthopedics and vascular surgery.